Protection against Parkinson's disease progression: clinical experience. - Wikidata - wikimedia - TriplyDB

Protection against Parkinson's disease progression: clinical experience.

Protection against Parkinson's disease progression: clinical experience.

http://www.wikidata.org/entity/Q37131239

about

Gene therapy in Parkinson's disease: rationale and current status Effects of dietary factors on levodopa pharmacokinetics.Nicotine as a potential neuroprotective agent for Parkinson's disease.Functional reduction of SK3-mediated currents precedes AMPA-receptor-mediated excitotoxicity in dopaminergic neurons.Protein S-nitrosylation in health and disease: a current perspective.Experimental therapeutics for dystonia.alpha-Synuclein: a therapeutic target for Parkinson's disease?Minocycline restores striatal tyrosine hydroxylase in GDNF heterozygous mice but not in methamphetamine-treated mice.Glial cells as players in parkinsonism: the "good," the "bad," and the "mysterious" glia.What's in the pipeline for the treatment of Parkinson's disease?Antioxidant enzyme gene transfer for ischemic diseases.Defective autophagy in Parkinson's disease: role of oxidative stress.From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors.Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease.Mavoglurant as a treatment for Parkinson's disease.Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid.Neuroprotective effect of naphtha[1,2-d]thiazol-2-amine in an animal model of Parkinson's disease.Microglia and CNS Interleukin-1: Beyond Immunological Concepts.

P2860

Q22241423-DFA33FF6-4761-4E14-AB8D-362D2B38E5C5 Q34109657-55AD9D5A-689B-4EA1-A7A8-DA70D02A380C Q34281003-00B273C3-AD69-48E3-B152-3C7EC2D68332 Q34995536-633CC1BF-E22E-4743-9FB9-1CE0375D18FC Q35020178-5C977184-2251-4F30-8DA1-E20F94AFB527 Q36569704-EC198806-7284-4C48-9768-92A9641A3920 Q37070916-86146140-DF98-4B67-8E09-112597B51903 Q37103483-054BAD91-36E4-4951-B4F5-F5ACB6F22FD6 Q37333346-93693ACA-4D0F-4255-AAD7-1156FC14CD57 Q37352050-7B8BB767-FD98-445D-9399-73F5415FBF53 Q37398189-0A138606-6D52-4D8D-A392-9B5BBF6AFCAF Q38035191-589E9002-DE16-45DA-A230-D3804F43B031 Q38040128-65F361C0-46C0-41B1-BA22-163F80A633EC Q38134903-CEC12BEC-BF03-48BF-AC5C-3A5F23CF3699 Q38222814-78307DD1-436C-4BD1-8D0E-CEA58EFD695E Q42870393-CF8B2B35-D185-4216-B978-A859ACDCBD5E Q46322181-C8B4641B-2163-43BF-B820-32A5804032AB Q49798820-73C39B60-A95A-4EF9-A1D7-18ECE2FC33BF

P2860

Protection against Parkinson's disease progression: clinical experience.

http://www.wikidata.org/entity/Q37131239

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Protection against Parkinson's disease progression: clinical experience.

@en

Protection against Parkinson's disease progression: clinical experience.

@nl

type

label

Protection against Parkinson's disease progression: clinical experience.

@en

Protection against Parkinson's disease progression: clinical experience.

@nl

prefLabel

Protection against Parkinson's disease progression: clinical experience.

@en

Protection against Parkinson's disease progression: clinical experience.

@nl

P1433

Q37131239-3572372E-EE2E-403D-86C1-451E6009B56F

P1476

Q37131239-0AAD48EF-E6EC-4AC2-A765-CC2D68C0AD13

P2093

Q37131239-6F99F5A9-4AF7-410A-9712-5AA45253765F

Q37131239-9966F7EC-719B-4EC2-92CD-DF38FCD309A5

P2860

Q37131239-00CA29D0-35EF-4EB6-BD4D-C5596F1F5742

Q37131239-0E2A0454-43A8-4691-9B5D-A898C5F4E590

Q37131239-0E3998E6-F860-4448-80E2-EFA4E1304CD1

Q37131239-0F90065B-CB3D-47A5-AE3A-0089A35A47EA

Q37131239-126D0D06-E5E3-4048-9D35-5BC61E9DF56A

Q37131239-13AFAE9A-3575-473F-B770-6E9F169C9C59

Q37131239-14BFA0C2-6892-4871-8906-A7AF98250C64

Q37131239-1B1AF8BC-08FB-4891-AA53-761C36A84689

Q37131239-1E601990-9D2E-4CFB-B55E-7098AC58FBFF

Q37131239-1FEFA302-9CF4-4624-BBB3-A3737C3D4106

P2888

Q37131239-EA476EF5-3175-465A-BF7D-483C2FB4FBE7

P304

Q37131239-66E57536-7BA9-4487-A8D0-371C26E22EEE

P31

Q37131239-0C22765B-9D5E-4D01-BE4C-2D23ADDC69D5

P356

Q37131239-E462F0D5-4761-4BB9-80B9-357ED40BEF65

P433

Q37131239-1FAF586E-D084-456C-BF59-A7D42238603B

P478

Q37131239-D9DB4767-8D5F-4851-B026-5F881747893C

P577

Q37131239-D2796672-8733-4D32-AF3B-29991129338C

P5875

Q37131239-AB3B540B-DB33-4A23-9B06-3DE3EB96DD56

P6179

Q37131239-C4336543-4AAE-4239-9841-CACCEEDD51AE

P698

Q37131239-F87FD2EC-7B97-4420-BBC3-AE45CDB23ABC

P921

Q37131239-6DD3C4B1-91EE-45AA-A40D-013D04E0E27B

P932

Q37131239-F333B84D-2855-4E62-9C8C-C992D11D0848

P356

J.NURT.2008.01.007

P1433

Neurotherapeutics

P1476

Protection against Parkinson's disease progression: clinical experience.

@en

P2093

Danette C Taylor

http://www.w3.org/2001/XMLSchema#string

Peter A LeWitt

http://www.w3.org/2001/XMLSchema#string

P2860

Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease

The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases

Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl

TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial

Ageing and Parkinson's disease: substantia nigra regional selectivity

P2888

j.nurt.2008.01.007

P304

210-225

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NURT.2008.01.007

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5457261

http://www.w3.org/2001/XMLSchema#string

P6179

1052879705

http://www.w3.org/2001/XMLSchema#string

P698

18394564

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

5084164

http://www.w3.org/2001/XMLSchema#string